The global cancer supportive care drugs market size was USD 21.40 billion in 2023, calculated at USD 21.85 billion in 2024 and is projected to surpass around USD 26.90 billion by 2034, expanding at a CAGR of 2.1% from 2024 to 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Supportive Care Drugs Market
5.1. COVID-19 Landscape: Cancer Supportive Care Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Supportive Care Drugs Market, By Therapeutic Class
8.1. Cancer Supportive Care Drugs Market Revenue and Volume, by Therapeutic Class, 2024-2034
8.1.1 ESA (Erythropoiesis Stimulating Agents)
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. G-CSFs (Granulocyte Colony Stimulating Factors)
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Antiemetics
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
8.1.4. Bisphosphonates
8.1.4.1. Market Revenue and Volume Forecast (2021-2034)
8.1.5. Opioids
8.1.5.1. Market Revenue and Volume Forecast (2021-2034)
8.1.6. NSAIDs (Non-Steroidal Auto Inflammatory Drugs)
8.1.6.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 9. Global Cancer Supportive Care Drugs Market, By Application
9.1. Cancer Supportive Care Drugs Market Revenue and Volume, by Application, 2024-2034
9.1.1. Breast Cancer
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Stomach Cancer
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
9.1.3. Colorectal Cancer
9.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1.4. Liver Cancer
9.1.4.1. Market Revenue and Volume Forecast (2021-2034)
9.1.5. Prostate Cancer
9.1.5.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 10. Global Cancer Supportive Care Drugs Market, By Distribution Channel
10.1. Cancer Supportive Care Drugs Market Revenue and Volume, by Distribution Channel, 2024-2034
10.1.1. Drug pharmacies/ Retail pharmacies
10.1.1.1. Market Revenue and Volume Forecast (2021-2034)
10.1.2. Hospital Pharmacies
10.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Volume Forecast (2021-2034)
Chapter 11. Global Cancer Supportive Care Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.1.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.1.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.1.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.1.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.2.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.2.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.2.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.2.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.2.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.3.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.3.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.3.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.3.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.4.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.4.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.4.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.4.7.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.5.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.5.4.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Therapeutic Class (2021-2034)
11.5.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel (2021-2034)
Chapter 12. Company Profiles
12.1. Merck & Co.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novartis AG
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. F. Hoffman-La Roche AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Johnson & Johnson
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. GlaxoSmithKline Plc
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Helsin Healthcare SA
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Baxter International Inc
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample